Revenue Breakdown

Financials in millions USD. Fiscal year is November - October.

Millions USD. Fiscal year is Nov - Oct.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016	FY 2015	FY 2014	FY 2013	FY 2012
Period Ending	Jan '26 Jan 31, 2026	Oct '25 Oct 31, 2025	Oct '24 Oct 31, 2024	Oct '23 Oct 31, 2023	Oct '22 Oct 31, 2022	Oct '21 Oct 31, 2021	Oct '20 Oct 31, 2020	Oct '19 Oct 31, 2019	Oct '18 Oct 31, 2018	Oct '17 Oct 31, 2017	Oct '16 Oct 31, 2016	Oct '15 Oct 31, 2015	Oct '14 Oct 31, 2014	Oct '13 Oct 31, 2013	Oct '12 Oct 31, 2012
Life Sciences & Diagnostics Markets Revenue	2.76B	2.73B	2.47B
Life Sciences & Diagnostics Markets Revenue Growth	1.17%	10.54%	-
Agilent CrossLab Revenue (Post-FY2024 Reporting)	2.97B	2.91B	2.75B
Agilent CrossLab Revenue (Post-FY2024 Reporting) Growth	2.13%	5.86%	-
Applied Markets Revenue	1.34B	1.31B	1.30B
Applied Markets Revenue Growth	1.75%	1.31%	-
Revenue (Total)	7.07B	6.95B	6.51B
Revenue (Total) Growth	1.68%	6.73%	-4.73%

Revenue Breakdown 2

Financials in millions USD. Fiscal year is November - October.

Millions USD. Fiscal year is Nov - Oct.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016	FY 2015	FY 2014	FY 2013	FY 2012
Period Ending	Jan '26 Jan 31, 2026	Oct '25 Oct 31, 2025	Oct '24 Oct 31, 2024	Oct '23 Oct 31, 2023	Oct '22 Oct 31, 2022	Oct '21 Oct 31, 2021	Oct '20 Oct 31, 2020	Oct '19 Oct 31, 2019	Oct '18 Oct 31, 2018	Oct '17 Oct 31, 2017	Oct '16 Oct 31, 2016	Oct '15 Oct 31, 2015	Oct '14 Oct 31, 2014	Oct '13 Oct 31, 2013	Oct '12 Oct 31, 2012
Life Sciences & Applied Markets Revenue	-	-	3.22B
Life Sciences & Applied Markets Revenue Growth	-	-	-8.40%
Diagnostics & Genomics Revenue	-	-	1.65B
Diagnostics & Genomics Revenue Growth	-	-	-5.93%
Agilent CrossLab Revenue (Pre-FY2025 Reporting)	-	-	1.64B
Agilent CrossLab Revenue (Pre-FY2025 Reporting) Growth	-	-	4.85%
Revenue (Total)	7.07B	6.95B	6.51B
Revenue (Total) Growth	1.68%	6.73%	-4.73%

Financials in millions USD. Fiscal year is November - October.

Millions USD. Fiscal year is Nov - Oct.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016	FY 2015	FY 2014	FY 2013	FY 2012
Period Ending	Jan '26 Jan 31, 2026	Oct '25 Oct 31, 2025	Oct '24 Oct 31, 2024	Oct '23 Oct 31, 2023	Oct '22 Oct 31, 2022	Oct '21 Oct 31, 2021	Oct '20 Oct 31, 2020	Oct '19 Oct 31, 2019	Oct '18 Oct 31, 2018	Oct '17 Oct 31, 2017	Oct '16 Oct 31, 2016	Oct '15 Oct 31, 2015	Oct '14 Oct 31, 2014	Oct '13 Oct 31, 2013	Oct '12 Oct 31, 2012
Life Sciences & Diagnostics Markets Income from Operations	528.00M	536.00M	484.00M
Life Sciences & Diagnostics Markets Income from Operations Growth	-1.49%	10.74%	-
Agilent CrossLab Income from Operations (Post-FY2024 Reporting)	965.00M	946.00M	925.00M
Agilent CrossLab Income from Operations (Post-FY2024 Reporting) Growth	2.01%	2.27%	-
Applied Markets Income from Operations	310.00M	301.00M	312.00M
Applied Markets Income from Operations Growth	2.99%	-3.53%	-
Operating Income (Other)	-347.00M	-304.00M	-233.00M
Operating Income (Total)	1.46B	1.48B	1.49B
Operating Income (Total) Growth	-1.55%	-0.60%	10.22%

Financials in millions USD. Fiscal year is November - October.

Millions USD. Fiscal year is Nov - Oct.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016	FY 2015	FY 2014	FY 2013	FY 2012
Period Ending	Jan '26 Jan 31, 2026	Oct '25 Oct 31, 2025	Oct '24 Oct 31, 2024	Oct '23 Oct 31, 2023	Oct '22 Oct 31, 2022	Oct '21 Oct 31, 2021	Oct '20 Oct 31, 2020	Oct '19 Oct 31, 2019	Oct '18 Oct 31, 2018	Oct '17 Oct 31, 2017	Oct '16 Oct 31, 2016	Oct '15 Oct 31, 2015	Oct '14 Oct 31, 2014	Oct '13 Oct 31, 2013	Oct '12 Oct 31, 2012
Life Sciences & Applied Markets Income from Operations	-	-	877.00M
Life Sciences & Applied Markets Income from Operations Growth	-	-	-16.40%
Diagnostics & Genomics Income from Operations	-	-	320.00M
Diagnostics & Genomics Income from Operations Growth	-	-	-11.85%
Agilent CrossLab Income from Operations (Pre-FY2025 Reporting)	-	-	524.00M
Agilent CrossLab Income from Operations (Pre-FY2025 Reporting) Growth	-	-	13.18%
Operating Income (Total)	1.46B	1.48B	1.49B
Operating Income (Total) Growth	-1.55%	-0.60%	10.22%

Updated Jan 31, 2026. Data Source: Fiscal.ai.